The North Carolina Agricultural Biotechnology Advisory Council
Agricultural Bioscience Company and Entrepreneurial Profile System
Growing North Carolina’s AgBiotech Landscape:Accelerating Entrepreneurial Enterprises
North Carolina Biotechnology Center
UNC-
W/Ja
mie
Mon
creif
NCSU
Fore
stry D
epar
tmen
t
istoc
kpho
to.co
m
BioR
esou
rce In
tern
ation
al, In
c.
The Agricultural Bioscience Company and Entrepreneurial Profile System (AgBIOCEPS) is a database representing a sampling of entrepreneurial agbiotech companies that have unique technologies in North Carolina. They are seeking various funding, technology partners or licensing opportuni-ties to grow their technologies and companies. The purpose of AgBIOCEPS is to bring these companies to your attention as a potential funder, partner, or capital acquirer. The aggre-gated value of investment opportunities presented herein is approximately $30 million.
The North Carolina Biotechnology Center does not endorse, promote or make any representations regarding specific companies in the AgBIOCEPS portfolio. This portfolio is for information only.
Our mission is to promote North Carolina as an ideal place for agbiotech investments and collaborative events. Please contact the companies directly or contact us for more information.
Gwyn RiddickVice President of Agricultural Biotechnology [email protected]
Amber NiebauerAgBiotech Innovation [email protected]
Entrepreneurial Companies and Their Technologies are Key Drivers of Agricultural Biotechnology in North Carolina
Innovation in agriculture, agricultural biotechnology and other sciences are driving a new sector of opportunities for North Carolina. Over 70 agriculture related biotechnology companies call North Carolina home. They encompass technologies and products focused on waste remediation, environment, industrial compounds, medicinal compounds as well as traditional shelter, fuel and food. These companies are part of North Carolina’s diverse economic sectors of forestry, marine, agriculture, biofuels, medicines, and health. Entrepreneurial agriculture and agricultural biotechnology companies offer an important and exciting path towards a new ag-based bioeconomy.
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Advanced Animal Diagnostics Advanced Animal Diagnostics (AAD) is a research and development company creating its own intellectual property as
well as commercializing proprietary technology for rapid, on-farm animal diagnostic tests.
Technology and Product(s)
AAD is developing a diagnostic test for mastitis, the most
costly disease in the dairy industry. While the initial focus is
on cows that have just calved to detect mastitis, the
technology is well-suited to a host of other applications for
testing body fluids of production animals (e.g., rapid test for
subclinical endometritis or microbiology). AAD's goal is to
improve the profitability of livestock production while
helping to ensure a safe, abundant, affordable supply of
animal protein.
Patents Filed and/or Granted
2 filed, 17 licensed
Geographical Scope of Market
North America, Oceana, Western Europe and South America
Market Size
More than $1 billion
Customers
Progressive dairies and key opinion leaders
Competitive Advantage
Earlier, more accurate and rapid diagnosis on-farm.
Mobile technology reaches a largely untapped segment
for farm animal diagnostics. Uses the animal's own early
immune response as a way to identify exposure to
infectious organisms.
Type of Partners Sought
Dairies and research collaborators to work together on
economic field trials to demonstrate the value
proposition. Distribution partners worldwide with strong
existing relationships with dairies and skilled sales and
technical staff.
Type of Investment Sought
AAD recently secured $11 M in venture capital funding
for mastitis product commercialization. The firm is still
interested in grant funding for diagnostic technology in
the pipeline.
Amount of Funding Sought
N.A.
Funding Period
N.A.
Company Contact
Joy Parr Drach
President
1912 Highway 54 East, Suite 205
Durham NC 27713
(919) 544-0089
www.aadiagnostics.com
Key Data
Founded: 2001
Employment Range: 0-20
County: Durham
Region: Triangle
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Agile Sciences Inc. Agile Sciences has identified novel small molecules that inhibit and disperse bacterial biofilms. The company is
investigating multiple applications in medicine, agriculture, and industry.
Technology and Product(s)
Developing a technology that interferes with bacterial and
fungal communication, including their ability to form
biofilms. This technology provides a novel, highly effective,
method of treating crop diseases. The company is also
investigating dental, medical, and industrial applications of
this technology.
Patents Filed and/or Granted
2 granted (7,897,631; 7,906,544), 9 filed
Geographical Scope of Market
U.S. and Europe
Market Size
Not estimated
Customers
Companies with existing bactericidal and fungicidal products
Competitive Advantage
More effective, environmentally friendly, method for
treating crop diseases.
Type of Partners Sought
Large corporations
Type of Investment Sought
Licensing, grants
Amount of Funding Sought
N.A.
Funding Period
1 to 3 years
Company Contact
Keith Stoneback
Chief Executive Officer
1791 Varsity Drive, Suite 150
Raleigh NC 27606
(919) 457-3308
www.agilesci.com
Key Data
Founded: 2007
Employment Range: 0-20
County: Wake
Region: Triangle
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Algaen Corp. Algaen is exploring microalgae to develop, produce and market products and technologies for the nutraceutical,
pharmaceutical and bio-energy production industries.
Technology and Product(s)
Developing a biofuel production system using oil rich
microalgae as a feedstock. Seeks funding to commercialize
the technology for use in ground transportation and the
aviation industry.
Patents Filed and/or Granted
6 filed
Geographical Scope of Market
International
Market Size
$400 billion
Customers
Big oil companies with capacity to distribute the biofuel
Competitive Advantage
Oil and fuel production at an overall lower cost, from a
renewable source.
Type of Partners Sought
Oil companies, power companies, or auto manufacturers
Type of Investment Sought
Equity investment from VC or other interested parties
Amount of Funding Sought
$2 million dollar for a pilot scale facility and $10 million
for a small scale production facility
Funding Period
1 to 3 years
Company Contact
Fan Lu Ph.D.
Chief Executive Officer
925 W. Northwest Blvd.
Winston-Salem NC 27101
(336) 577-4354
www.algaen.com
Key Data
Founded: 2002
Employment Range: 0-20
County: Forsyth
Region: Piedmont Triad
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Avoca Inc. Avoca provides botanical extract products, toll processing services and product development solutions.
Technology and Product(s)
Custom developer and cGMP manufacturer of botanical
products and extracts. Commercial focus is on the production
of sclareolide, a fragrance stabilizer extracted from clary
sage. Largest extraction facility in North America, with an
annual extraction capacity of 90,000 tons.
Patents Filed and/or Granted
Granted (6,852,342; 7,588,759; 7,785,585) and other
proprietary information is protected through confidentiality
agreements
Geographical Scope of Market
Western Europe and Israel
Market Size
$30 million
Customers
Fragrance companies, companies needing contract extraction
development
Competitive Advantage
30 years of agricultural R&D experience, a group of
local growers, processing experience and expertise, and
a cutting-edge extraction facility.
Type of Partners Sought
N.A.
Type of Investment Sought
N.A.
Amount of Funding Sought
N.A.
Funding Period
Less than 3 months
Company Contact
David Peele Ph.D.
President
P.O. Box 129
Merry Hill NC 27957
(252) 482-2133
www.pharmachemlabs.com
Key Data
Founded: 1962
Employment Range: 51-100
County: Bertie
Region: East
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
BioResource International Inc. BioResource International discovers and develops enzymes to promote animal nutrition and environmental stewardship.
Technology and Product(s)
Offers cost-effective solutions to promote animal nutrition
and environmental responsibility. Animal feed enzyme
Versazyme® helps grow bigger and healthier livestock.
Valkerase®, based on a patented keratinase enzyme,
improves the efficiency and lowers the cost of poultry feather
meal production.
Patents Filed and/or Granted
8 granted (7,915,024; 6,613,505; 6,613,505; 5,712,147;
5,186,961; 5,171,682; 5,063,161; 4,959,311; 4,908,220)
Geographical Scope of Market
North and South America, Southeast Asia, and China
Market Size
$200 million
Customers
Large-scale poultry and swine production companies
Competitive Advantage
Superior performance of patent-protected products,
expertise, global partnerships and better value than
competitive products.
Type of Partners Sought
Seeking to license in new technologies or partner with
innovative companies to develop novel products.
Type of Investment Sought
No equity investment sought; seeking debt financing for
working capital
Amount of Funding Sought
Seeking up to $1 million line of credit
Funding Period
3 to 6 months
Company Contact
Giles Shih Ph.D., MBA
Chairman and Chief Executive Officer
627 Davis Drive, Suite 600
Durham NC 27713
(919) 993-3389
www.briworldwide.com
Key Data
Founded: 1999
Employment Range: 0-20
County: Durham
Region: Triangle
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Crop Microclimate Management Inc. Crop Microclimate Management (CMM) researches and develops technologies, based on natural plant biochemistry, that
enable farmers to improve crop productivity by managing and reducing the impact of environmental stresses.
Technology and Product(s)
CMM's research focus is on the exploitation of crop plants’
natural biochemistry to reduce the impact of environmental
stress factors such as excess heat and light, drought, frost and
salinity. Screen Duo™, is a dual mode-of-action product for
use in horticultural crops. 'G3' Technology is a family of
naturally occurring biochemicals, currently under
development, that are active against a number of stresses, at
very low rates of use, in all crops. The research pipeline
includes 4th and 5th generation technology platforms.
Patents Filed and/or Granted
2 filed
Geographical Scope of Market
Global
Market Size
Billions (U.S. $). Abiotic stress management is a nascent, but
rapidly growing new market.
Customers
Crop protection companies (licensing), agricultural
distributors and farmers
Competitive Advantage
Superior performance; low cost; ease of use; low/zero
environmental impact and low regulatory burden
Type of Partners Sought
Global or regional crop protection companies and
investors
Type of Investment Sought
Equity investment and licensing agreements
Amount of Funding Sought
$2.5 million to $5 million
Funding Period
1 to 3 years
Company Contact
Chuck Kupatt Ph.D.
President and R&D Director
P.O. Box 178
Apex NC 27502
(919) 624-4490
www.cropstress.com
Key Data
Founded: 2006
Employment Range: 0-20
County: Wake
Region: Triangle
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Galaxy Diagnostics Inc. Galaxy Diagnostics provides advanced molecular-based testing for Bartonella infection in both humans and animals
suffering from chronic diseases. The company is commercializing proprietary technologies developed at NCSU College
of Veterinary Medicine.
Technology and Product(s)
Galaxy is commercializing an advanced molecular detection
methodology for the hard-to-detect bacteria Bartonella.
EnrichmentPCR™ methodology was developed at the NC
State University College of Veterinary Medicine. This novel
testing methodology combines a patented enrichment media
with PCR detection and sequencing to significantly increase
Bartonella detection sensitivity.
Patents Filed and/or Granted
1 granted (7,115,385)
Geographical Scope of Market
International
Market Size
$130 million
Customers
Vets and physicians at universities, commercial laboratories,
and independent clinics; eventually pet owners and patients
Competitive Advantage
Most sensitive and reliable patent-protected detection
method supported by high quality clinical research
Type of Partners Sought
Large biotech firms with resources to spend on
compatible technologies including diagnostics,
antibiotics, and reagents
Type of Investment Sought
Angel investment to support development of commercial
infrastructure and early marketing, grants to support
clinical research and product development
Amount of Funding Sought
$500,000 to $1 million
Funding Period
1 to 3 years
Company Contact
Amanda Elam Ph.D.
President
P.O. Box 14346
Research Triangle Park NC 27709
(919) 313-9672
www.galaxydx.com
Key Data
Founded: 2007
Employment Range: 0-20
County: Durham
Region: Triangle
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
GrassRoots Biotechnology Inc. GrassRoots Biotechnology is an agricultural biotechnology company employing a systems biology approach to develop
enhanced biofuel and food crops.
Technology and Product(s)
GrassRoots’ RootArray platform enables non-invasive
imaging of gene expression (labeled with green florescent
protein) in developing plant roots. The RootArray along with
bioinformatic analysis of gene expression data sets yields
discoveries of gene promoters to regulate gene expression in
transgenic plants, as well as genes to enhance nitrogen
utilization and other high-value agronomic traits. The Root
Architecture Imaging platform will facilitate development of
crops with enhanced root structure for better nutrient and
water acquisition. These technologies will enhance
traditional agricultural and biofuel crops.
Patents Filed and/or Granted
1 granted and more than 10 filed
Geographical Scope of Market
International
Market Size
Billions
Customers
Multinational agricultural biotechnology companies,
Monsanto is chief customer currently
Competitive Advantage
Promoters and other gene expression elements that
produce better, more finely-tuned control of gene
expression and genes that enhance agronomic
productivity
Type of Partners Sought
Agricultural biotechnology, seed and biofuel companies
Type of Investment Sought
Commercial loan and financing through partnerships
Amount of Funding Sought
$4 million
Funding Period
1 to 3 years
Company Contact
Douglas Eisner
Chief Operating Officer
302 E. Pettigrew St.
Durham NC 27701
(919) 747-7407
www.grassrootsbio.com
Key Data
Founded: 2007
Employment Range: 21-50
County: Durham
Region: Triangle
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
GTCAllison LLC GTCAllison researches and develops novel diagnostic tests for animal pathogens.
Technology and Product(s)
Developing real-time PCR and microsphere based tests for
the molecular detection of animal pathogens and microsphere
based tests for the detection of antibodies to animal
pathogens. Other projects for clients are confidential.
Patents Filed and/or Granted
Proprietary information is protected through confidentiality
agreements and patents
Geographical Scope of Market
International
Market Size
Not estimated
Customers
Production animal companies, vaccine companies, university
and state diagnostic laboratories
Competitive Advantage
Lower overall cost due to less material used per test and
less time to generate test results, better specificity and
limits of detection
Type of Partners Sought
Production animal companies, vaccine companies,
university and state diagnostic laboratories
Type of Investment Sought
Capital to pay for attorney fees for filing of IP, to hire
employees, to hire an accounting firm that knows the
industry, and for licensing of technologies necessary to
commercialize aspects of GTCAllison’s own IP at a
reasonable cost
Amount of Funding Sought
Not currently seeking funding
Funding Period
N.A.
Company Contact
Scott Callison Ph.D.
Founder and Manager
153 Junction Road
Mocksville NC 27028
(336) 753-0707 laboratory; (336) 473-5525 cell
www.gtcallison.com
Key Data
Founded: 2006
Employment Range: 0-20
County: Davie
Region: Piedmont Triad
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Helical Sciences Inc. Helical Sciences is developing a rapid microbiological diagnostic product.
Technology and Product(s)
Developing microbiological diagnostics and kits for the rapid
identification of bacterial pathogens and toxic metals in food,
water, and pharmaceuticals. Validation on the first
commercial product has been completed and beta testing was
successful. Additional IP is being developed that can rapidly
determine other organic and inorganic contaminants in water
and irrigation systems.
Patents Filed and/or Granted
1 granted (7,214,492), several patents licensed, proprietary
information protected through confidentiality agreements
Geographical Scope of Market
International
Market Size
$14 billion globally (U.S. approx. $6 billion)
Customers
Food producers/processors, municipal water suppliers,
pharmaceutical and cosmetics manufacturers, hospitals and
healthcare providers, diagnostic laboratories
Competitive Advantage
10-20 times faster than current technologies at very
competitive costs, will allow customers to drastically
reduce microbiological testing costs while greatly
improving consumer safety.
Type of Partners Sought
A strategic business partner already established in the
microbiological diagnostic market, regulatory review
and assistance would also be helpful
Type of Investment Sought
Funding from strategic partners, relevant grants
Amount of Funding Sought
$3 million
Funding Period
1 to 3 years
Company Contact
Greg Bowers
President and Chief Executive Officer
3903 Westmount Drive
Greensboro NC 27410
(336) 601-9945
www.helicalsciences.com
Key Data
Founded: 2007
Employment Range: 0-20
County: Guilford
Region: Piedmont Triad
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
JABB of the Carolinas Inc. JABB develops fungal pesticides and provides biopesticide products that are safe, effective and economical alternatives to
conventional pesticides.
Technology and Product(s)
Biological insecticide balEnce™ from the naturally
occurring fungus, Beauveria bassiana. Through the
application of novel, proprietary, production technologies
Jabb can produce commercial quantities of the fungus at
economical costs and which meet all regulatory
requirements. Custom development and manufacture of
fungal products is also available.
Patents Filed and/or Granted
Proprietary information is protected by restrictive access to
areas of production
Geographical Scope of Market
The Americas, Africa, and Asia
Market Size
$4 million
Customers
Livestock producers and consumers
Competitive Advantage
Can build a very specific product to target a narrow
range of pests, allowing other beneficial insects to
survive, with no toxicity outside of the target species.
Type of Partners Sought
N.A.
Type of Investment Sought
N.A.
Amount of Funding Sought
N.A.
Funding Period
N.A.
Company Contact
James Arends Ph.D.
President
P.O. Box 310
Pine Level NC 27568-0310
(919) 965-9007
www.jabb.bz
Key Data
Founded: 1994
Employment Range: 0-20
County: Johnston
Region: Triangle
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Medicago USA Inc. Medicago uses tobacco leaves to produce influenza vaccines.
Technology and Product(s)
Technologies related to the use of virus-like-particles (VLPs)
for vaccine development and production. Using whole living
plants as hosts for transient protein expression, the Proficia™
technology is a rapid, flexible, high yielding and robust
production system for vaccines, antibodies and recombinant
proteins. Initial focus is on influenza strain vaccines.
Patents Filed and/or Granted
4 granted (6,420,548; 7,125,978; 5,990,385; 6,492,134) and
more than 300 patents and patent applications filed
Geographical Scope of Market
North America, Asia-Pacific and Europe
Market Size
Billions
Customers
U.S. government (DARPA), large biopharma
Competitive Advantage
Vaccine production at lower costs and with shorter
turnaround times than competitive methods. Technology
is capable of developing almost any vaccine candidate.
Type of Partners Sought
Large biopharmaceutical companies, government
collaborators, process scale-up research contractors
Type of Investment Sought
Equity investments and grants
Amount of Funding Sought
Open
Funding Period
N.A.
Company Contact
Michael Wanner
Vice President, U.S. Operations
P.O. Box 14545
Durham NC 27709
(919) 805-3501
www.medicago.com
Key Data
Founded: 1999
Employment Range: 51-100
County: Durham
Region: Triangle
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Piedmont Pharmaceuticals Piedmont Pharmaceuticals is a specialty pharmaceutical company focused on human and animal health therapeutics with
expertise in parasitology and drug delivery systems.
Technology and Product(s)
Actively developing products and novel drug delivery
systems for human and animal health. Products include a
companion animal soft chew medicine delivery platform
recently purchased by Bayer, a fly control product for horses
licensed by Pfizer, and a head lice product commercialized
internationally.
Patents Filed and/or Granted
Multiple patents filed
Geographical Scope of Market
International
Market Size
$5 billion globally
Customers
Major to mid-sized pharmaceutical companies
Competitive Advantage
Novel delivery mechanisms for both generics and new
actives, as well as development of new products to target
the largest companion and food animal disease areas.
Type of Partners Sought
R&D, manufacturing and distribution partners
Type of Investment Sought
N.A.
Amount of Funding Sought
N.A.
Funding Period
N.A.
Company Contact
Eric Barnett M.D.
Executive VP, Business Development and Marketing
204 Muirs Chapel Road, Suite 200
Greensboro NC 27410-6173
(336) 544-0320
www.piedmontpharma.com
Key Data
Founded: 2001
Employment Range: 0-20
County: Guilford
Region: Piedmont Triad
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
SoyMeds Inc. Soymeds is a biotechnology company focused on the development and validation of soybean seed-derived, protein-based
therapeutics to diagnose, treat and prevent disease.
Technology and Product(s)
Developing soybean seed-based therapeutics
(immunomodulators such as vaccines and toleragens,
antigens and diagnostic) to prevent, treat, cure and diagnose
disease. Products are stable for >5 years, and can be
administered orally (as formulated soymilk) or purified.
Toleragens can be targeted to specific mucosal cell types and
have the potential to limit immune responses associated with
food allergies and autoimmune disease. Purified diagnostics
can be used as cost-effective "bio-betters" in analytical
assays and as reagents for novel medical devices.
Patents Filed and/or Granted
1 granted (7,723,570), 2 filed
Geographical Scope of Market
U.S. initially, hope to expand into International markets
Market Size
$10 million to $100 million
Customers
Pharmaceutical companies
Competitive Advantage
Lower costs, bioequivalency, simplified purification and
storage requirements, and elimination of cold-chain will
allow the development of new products to address unmet
needs.
Type of Partners Sought
Industrial and pharmaceutical for production of specific
products; BSL-2 greenhouse space, manufacturing and
implementation, regulatory; and longer term, marketing
and distribution.
Type of Investment Sought
Grants and awards
Amount of Funding Sought
$500,000 to $1 million per year, $3 million to $5 million
to move lead products forward
Funding Period
1 to 5 years
Company Contact
Kenneth Piller Ph.D.
President and Co-Founder
18616 Dembridge Drive
Davidson NC 28036
(704) 728-9753
www.soymeds.com
Key Data
Founded: 2005
Employment Range: 0-20
County: Mecklenburg
Region: Greater Charlotte
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Trana Discovery Inc. Trana Discovery is an anti-infective drug discovery technology company that helps its partners find new classes of
compounds for the treatment of bacterial, viral, and fungal infectious diseases.
Technology and Product(s)
Technology for discovering new agents to treat bacterial,
viral and fungal infectious diseases. Proprietary high-
throughput screening assays identify compounds that can
inhibit the target pathogen’s ability to use transfer RNA
essential for propagation. Initial focus human pathogens,
interested in vet/ag applications of technology. Licensing
opportunities are available for exclusive rights to new drug
classes.
Patents Filed and/or Granted
Several patents granted (7,598,040), licensed (6,461,815;
6,962,785) and filed
Geographical Scope of Market
International
Market Size
$3 billion to $5 billion (HIV), $1 billion to $3 billion (Staph)
Customers
Pharmaceutical companies, academic institutions and other
organizations for use in compound libraries
Competitive Advantage
A novel class of antibiotics and antivirals for the
treatment of pathogens including pathogens resistant to
currently available agents, identifying new compounds
with the ability to block protein synthesis in pathogens.
Type of Partners Sought
Pharma companies willing to invest in discovered
compounds and discovery assay
Type of Investment Sought
Licensing
Amount of Funding Sought
N.A.
Funding Period
1 to 3 years
Company Contact
Steve Peterson
Chief Executive Officer
659-193 Cary Towne Blvd.
Cary NC 27511
(919) 342-6192 or (866) 390-3452
www.tranadiscovery.com
Key Data
Founded: 2001
Employment Range: 0-20
County: Wake
Region: Triangle
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Venganza Inc. Venganza uses proprietary RNA interference technology to control plant pests (fungi, insects, nematodes, etc.) and reduce
the application of fungicides and other pesticides.
Technology and Product(s)
Proprietary RNA interference or “gene silencing” technology
to control plant pests, reducing the need for pesticide
application. Transgenic plants contain proprietary genes that
effectively control crop pests, while being safe for humans
and the environment. Proof of concept has been
demonstrated with four fungal diseases in tobacco, soybeans
and corn.
Patents Filed and/or Granted
2 filed
Geographical Scope of Market
International
Market Size
$100 million
Customers
Individual farmers through major plant biotechnology
companies
Competitive Advantage
Unique approach to plant disease resistance, reducing
crop losses, pesticide usage and mycotoxin poisoning of
consumers.
Type of Partners Sought
N.A.
Type of Investment Sought
N.A.
Amount of Funding Sought
$350,000 per year as we complete the R&D phase = ca.
4 years
Funding Period
1 to 3 years
Company Contact
Chuck Niblett Ph.D.
President
840 Main Campus Drive, Suite 3560
Raleigh NC 27606
(919) 995-1643
www.venganzainc.com
Key Data
Founded: 2004
Employment Range: 0-20
County: Wake
Region: Triangle
North Carolina Biotechnology Center AgBIOCEPS survey, updated March 2011
Xanofi Inc. Xanofi is an advanced nanofiber manufacturing firm, commercializing a technology for producing low-cost,
functionalized nanofibers for applications in energy, medicine and filtration.
Technology and Product(s)
Patented technology was developed at NC State University
for creating nanofibers through the use of shear force in
liquids. Process is currently in commercial scale-up
development, researching various products in the pipeline
during this time, with a focus on lighting, energy and
filtration applications.
Patents Filed and/or Granted
1 filed
Geographical Scope of Market
U.S. initially, hope to expand into International markets
Market Size
$100 million
Customers
Manufacturers of products containing nanofiber materials
Competitive Advantage
Development of customized nanofibers at reduced cost
and increased efficiency, that can be incorporated into
textiles and other products without the use of expensive
equipment.
Type of Partners Sought
Co-development partnerships with future customers, end
product manufacturers
Type of Investment Sought
Grants, equity investment
Amount of Funding Sought
N.A.
Funding Period
1 to 3 years
Company Contact
Pete Geisen
Vice President, Product Development
543 Pylon Drive
Raleigh NC 27606
(919) 699-0260
xanofi.com
Key Data
Founded: 2010
Employment Range: 0-20
County: Wake
Region: Triangle
Notes
Notes
Statewide Effort
North Carolina is home to a broad range of natural resources and scientific knowledge that, when combined, can create biotechnology-related jobs across our state. Agricultural biotechnolgy companies stretch from the mountains to the coast. In addition to the Center’s headquarters in Research Triangle Park, the Center operates five regional offices: Asheville, Charlotte, Greenville, Winston-Salem, and Wilmington. The region is indicated on each company profile. Below is contact information for each regional office:
Western Office (Asheville)www.ncbiotech.org/west828-670-3394
Greater Charlotte Office www.ncbiotech.org/charlotte704-687-8563
Eastern Regional Office (Greenville)www.ncbiotech.org/east 252-328-9981
Piedmont Triad Office (Winston-Salem)www.ncbiotech.org/triad 336-725-6672
Southeastern Office (Wilmington)www.ncbiotech.org/southeast 910-763-5747
15 T.W. Alexander Drive · Research Triangle Park, NC 27709-3547 · ncbiotech.org/agbioAsheville · Charlotte · Greenville · Research Triangle Park · Wilmington · Winston-Salem
The North Carolina Biotechnology Center is a private, non-profit corporation supported by the N.C. General Assembly. Its mission is to provide long-term economic and societal benefits to North Carolina by supporting biotechnology research, business, education and strategic policy statewide.
UNC-
W/Ja
mie
Mon
creif
Stev
e McK
eand
/tree
impr
ovem
ent.o
rg
Syng
enta
istoc
kpho
to.co
m